BioCentury Hot Topics

The era of human-first discovery is here, and it’s colliding with big data and new analytical tools to create an imperative to ensure drug targets play a causal role in disease. Illuminating causal human biology is the goal. How to accomplish this is the question.

BioCentury’s deep dive into U.S.-China life sciences public policy, from the Biosecure Act to executive orders. BioCentury’s reporting brings readers inside Congress and the White House as legislators and government officials seek to balance national security, commercial competition, privacy and geopolitical rivalry.

With the first wave of GLP-1 therapies poised to become the biggest blockbusters in biopharma history, the focus turns to what's next in obesity, including combination therapies and new mechanisms to address an improved quality and duration of weight loss and co-morbidities

BioCentury's deep dive into the law, exploring its impacts, explaining how the choices the federal government is making in implementing it, and options for medical product developers as they navigate the new landscape

BioCentury documents the approval of new modality therapies in a complimentary chart suitable for printing and display, or incorporation into a presentation

From the origins of the orphan drug industry to recent initiatives to expand and accelerate drug development for rare diseases